Stockholm - Delayed Quote SEK

Perpetua Medical AB (publ) (PERP-B.ST)

4.2900
0.0000
(0.00%)
At close: May 22 at 5:15:11 PM GMT+2
Loading Chart for PERP-B.ST
  • Previous Close 4.2900
  • Open 4.0200
  • Bid 3.9100 x --
  • Ask 4.1200 x --
  • Day's Range 4.2900 - 4.2900
  • 52 Week Range 1.6800 - 8.2500
  • Volume 708
  • Avg. Volume 6,112
  • Market Cap (intraday) 19.398M
  • Beta (5Y Monthly) 2.42
  • PE Ratio (TTM) --
  • EPS (TTM) -1.4500
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Apr 16, 2021
  • 1y Target Est --

Perpetua Medical AB (publ) provides products and solutions for use of injectable drugs in Sweden. The company offers DrugLog, a solution for reducing medication errors in pharmacy; WasteLog, a device that analysis waste and returns of injectable controlled substances; and PrepLog, a DrugLog based technology platform that integrated prescription software or medication management system for the test of drug preparations. The company formerly known as Pharmacolog i Uppsala AB (publ) and changed its name to Perpetua Medical AB (publ) in April 2024. Perpetua Medical AB (publ) was incorporated in 2007 and is headquartered in Uppsala, Sweden. Perpetua Medical AB (publ) operates as a subsidiary of Nolsterby Invest AB.

perpetuamedical.se

3

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PERP-B.ST

View More

Performance Overview: PERP-B.ST

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

PERP-B.ST
0.23%
OMX Stockholm 30 Index (^OMX)
0.14%

1-Year Return

PERP-B.ST
77.86%
OMX Stockholm 30 Index (^OMX)
6.13%

3-Year Return

PERP-B.ST
96.82%
OMX Stockholm 30 Index (^OMX)
22.82%

5-Year Return

PERP-B.ST
97.23%
OMX Stockholm 30 Index (^OMX)
59.41%

Compare To: PERP-B.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PERP-B.ST

View More

Valuation Measures

Annual
As of 5/23/2025
  • Market Cap

    19.40M

  • Enterprise Value

    16.18M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.21

  • Price/Book (mrq)

    2.95

  • Enterprise Value/Revenue

    1.84

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -35.64%

  • Return on Assets (ttm)

    -9.89%

  • Return on Equity (ttm)

    -25.16%

  • Revenue (ttm)

    6.94M

  • Net Income Avi to Common (ttm)

    -2.47M

  • Diluted EPS (ttm)

    -1.4500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.4M

  • Total Debt/Equity (mrq)

    36.81%

  • Levered Free Cash Flow (ttm)

    5.51M

Research Analysis: PERP-B.ST

View More

Company Insights: PERP-B.ST

Research Reports: PERP-B.ST

View More